Last reviewed · How we verify

NCT07318285: OPTILID

Targeted Lidocaine Infusion for Pain Reduction in Office Hysteroscopy

Not yet recruiting NA Last updated 5 January 2026
What this trial tests

NA trial testing Lidocaine %2 ampoule in Hysteroscopy / Methods in 208 participants. Not yet recruiting.

Timeline
1 February 2026
Primary endpoint
30 December 2028
30 December 2029

Quick facts

Lead sponsorYAARA TABIB
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposeprevention
Enrollment208
Start date1 February 2026
Primary completion30 December 2028
Estimated completion30 December 2029

Drugs / interventions tested

Conditions studied

Sponsor

YAARA TABIB

Who can join

18 and older, female only, with Hysteroscopy / Methods or Lidocaine Infusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to find out whether a small amount of lidocaine (a common local anesthetic) can reduce pain during office hysteroscopy - a procedure used to look inside the uterus. The study will compare lidocaine to saline (salt water) to see which one helps more with pain relief. Participants will: 1. Receive either lidocaine or saline gently applied inside the cervix right before the procedure 2. Undergo the hysteroscopy as planned 3. Be asked to rate their pain and satisfaction after the procedure Lidocaine is commonly and safely used in dental and gynecological procedures. Participation is voluntary, and the procedure itself will not change.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Lidocaine %2 ampoule

Trials testing the same drug.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07318285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing